M&A Deal Summary |
|
|---|---|
| Date | 2005-01-20 |
| Target | Angiosyn |
| Sector | Life Science |
| Buyer(s) | Pfizer |
| Sellers(s) | Alta Partners |
| Deal Type | Add-on Acquisition |
| Deal Value | 527M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1849 |
| Sector | Life Science |
| Employees | 81,000 |
| Revenue | 63.6B USD (2024) |
Pfizer is a global pharmaceutical company that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare products, including medicines and vaccines. The company's portfolio includes treatments across a broad spectrum of areas such as oncology, cardiology, neurology, and infectious diseases, among others. Pfizer was founded in 1849 and is based in New York, New York.
| DEAL STATS | # |
|---|---|
| Overall | 4 of 46 |
| Sector: Life Science M&A | 4 of 41 |
| Type: Add-on Acquisition M&A Deals | 3 of 33 |
| State: California M&A | 1 of 14 |
| Country: United States M&A | 4 of 33 |
| Year: 2005 M&A | 1 of 2 |
| Size (of disclosed) | 19 of 24 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2003-12-21 |
Esperion Therapeutics
Plymouth, Michigan, United States Development stage biotechnology company focused on cardiovascular drugs. Drug discovery and development company focused on therapies that prevent, treat and reverse cardiovascular and metabolic diseases. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2005-08-15 |
Bioren
San Carlos, California, United States Bioren, Inc. is a antibody discovery and optimization company developing a rational approach to antibody engineering. Bioren utilizes its patented Walk Through Mutagenesis (WTM) technology to design antibodies in an in vitro and fully automated system. |
Buy | - |
| Category | Venture Capital Firm |
|---|---|
| Founded | 1996 |
| PE ASSETS | 2.6B USD |
| Size | Large |
| Type | Sector Focused |
Alta Partners is a venture capital firm that targets investments in early and later stage life science companies, including biopharmaceuticals, medical technology, and information technology businesses. Alta was formed as an early stage investor but has since expanded its investment range to provide later stage growth capital to private and young public companies. Alta was established in 1996 and is headquartered in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 21 of 85 |
| Sector: Life Science M&A | 12 of 65 |
| Type: Add-on Acquisition M&A Deals | 13 of 45 |
| State: California M&A | 12 of 41 |
| Country: United States M&A | 19 of 75 |
| Year: 2005 M&A | 2 of 6 |
| Size (of disclosed) | 7 of 23 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2005-01-01 |
Silence Therapeutics
London, United Kingdom Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Silence Therapeutics proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Silence Therapeutics was incorporated in 1994 and is based in London, United Kingdom. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2005-04-19 |
Orphan Medical
Minnetonka, Minnesota, United States Orphan Medical is a specialty pharmaceutical company which acquires, develops, and markets pharmaceuticals for inadequately treated and uncommon diseases, including sleep disorders. The Company recently received regulatory approval in the United States for Xyrem, a therapeutic for the treatment of cataplexy. Orphan Medical was a public company traded on Nasdaq under the symbol ORPH. |
Sell | $123M |
